摘要
目的探讨雷珠单抗联合半量睫状体光凝术治疗新生血管性青光眼(NVG)的效果观察。方法选取2021年1月至2023年1月在首都医科大学宣武医院治疗的NVG患者110例(110眼)作为研究对象。在组间基线特征匹配的原则上,按照简单随机数表法将入组NVG患者分为观察组与对照组,各55例。对照组行半量睫状体光凝术,观察组在其基础上加用雷珠单抗治疗每月1次,连续3次。比较两组新生血管消退时间、治疗成功率、术后并发症及6个月复发率,治疗后1个月、3个月和6个月最佳矫正视力(BCVA)和眼压恢复情况,及治疗前、治疗3个月后血清检测指标[血清白细胞介素-1β(IL-1β)、IL-6和血管内皮生长因子水平(VEGF)]。结果观察组患者新生血管消退时间及成功率优于对照组(P<0.05)。治疗后1个月、3个月和6个月,两组患者BCVA均比治疗前明显升高,但组间比较差异无统计学意义(P>0.05);两组患者眼压均比治疗前明显降低,且观察组各时间点更低,差异有统计学意义(P<0.05)。治疗后两组患者IL-1β、IL-6和VEGF水平均低于治疗前,且观察组比对照组更低(P<0.05)。两组患者的并发症发生率及术后复发率差异均无统计学意义(P>0.05)。结论雷珠单抗联合半量睫状体光凝术治疗NVG成功率较高,可以有效改善眼压和炎症水平。
Objective To explore the improvement effect of ranibizumab combined with half-volume ciliary body photocoagulation in the treatment of neovascular glaucoma(NVG).Method A total of 110 patients(110 eyes)with NVG treated in the hospital were enrolled as the research objects between January 2021 and January 2023.They were divided into two groups,55 cases in each group.The control group was treated with half-volume ciliary body photocoagulation,while observation group was additionally treated with leizumab once a month for 3 consecutive times.The disappearance time of neovascularization,success rate of treatment,postoperative complications,recurrence rate at 6 months after surgery,BCVA,intraocular pressure,IL-1β,IL-1β,IL-6 and VEGF were compared before and after treatment.Result The success rate of neovascularization time and recurrence rate 6 months after operation in the observation group were better than those in the control group(P<0.05).At 1 month,3 months and 6 months after treatment,BCVA in both groups was significantly increased(P<0.05).After treatment,intraocular pressure in both groups was significantly decreased,which was lower in observation group(P<0.05).After treatment,levels of IL-1β,IL-6 and VEGF in both groups were decreased,which were lower in observation group(P<0.05).Conclusion Ranibizumab combined with half-volume ciliary body photocoagulation had high success rate in the treatment of NVG,which could effectively improve intraocular pressure and inflammation level,and reduce postoperative recurrence rate.
作者
边俊杰
张磊
刘大川
Bian Junjie;Zhang Lei;Liu Dachuan(Department of Ophthalmology,Xuanwu Hospital of Capital Medical University,Beijing 100053)
出处
《中国临床医生杂志》
2024年第4期400-403,共4页
Chinese Journal For Clinicians
基金
首都临床特色应用研究与成果推广(Z17110001017029)。
关键词
新生血管性青光眼
雷珠单抗
半量睫状体光凝术
视力
眼压
Neovascular glaucoma
Ranibizumab
Half-volume ciliary body photocoagulation
Visual acuity
Intraocular pressure
